|
|
|
|
Aastrom Biosciences, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new market report released
Refer to a friend 2010-03-10 22:53:16 - Aastrom Biosciences, Inc.- Pharmaceuticals & Healthcare - Deals and Alliances Profile - a new market research report on companiesandmarkets.com Aastrom Biosciences, Inc. - Pharmaceuticals & Healthcare - Deals...
|
|
|
High-Quality Cardiac Echo Offered at the Bedside
Advanced imaging features are offered by Sonosite for cardiac imaging.These include SonoHD imaging technology and SonoMB multibeam imaging technologies, which provide superior contrast resolution and tissue differentiation, supporting complete diagnostic...
|
|
|
Neovasc Inc. Receives CFIA Approval for Pericardial Tissue Products in Europe
-- Allows Export of Neovasc Tissue Products to Europe as an Intermediate Product Used in the Manufacture of Implantable Medical Devices -- TSX Venture Exchange: NVC VANCOUVER, Feb.25 /PRNewswire-FirstCall/ - Neovasc Inc. (TSXV: NVC), today announced...
|
|
|
Neovasc Inc. Receives CFIA Approval for Pericardial Tissue Products in Europe
-- Allows Export of Neovasc Tissue Products to Europe TSX Venture Exchange: NVC VANCOUVER 'Receipt of this CFIA approval makes it substantially easier for our European customers to import Neovasc's tissue products for incorporation into their own medical...
|
|
|
Study Sheds Light On Formation of Tissue-Engineered Vascular Grafts to Repair Heart Defect
(PhysOrg.com) -- A Yale School of Medicine study provides new understanding of the mechanisms that underlie how tissue engineered vascular grafts (TEVG) work.The paper is published this week in the online Early Edition of the Proceedings of the...
|
|
|
Yale Study Sheds Light On Formation of Tissue-Engineered Vascular Grafts to Repair Heart Defect
FOUND IN: Published: February 22, 2010 New Haven, Conn.A study provides new understanding of the mechanisms that underlie how tissue engineered vascular grafts (TEVG) work. The paper is published this week in the online Early Edition of the...
|
|
|
Evidence for tissue factor phosphorylation and its correlation with protease-activated receptor expression and the prognosis of primary breast cancer
Tissue factor (TF)-mediated protease-activated receptor (PAR)-2 signaling is associated with a promigratory, invasive and proangiogenic phenotype in experimental models of breast cancer and has been mechanistically coupled to phosphorylation of the TF...
|
|
|
Aastrom Biosciences Shareholders Approve All 2009 Proxy Proposals
About Aastrom Biosciences, Inc.Aastrom is a leader in regenerative medicine developing autologous cell products for the treatment of severe, chronic cardiovascular diseases. The Company's proprietary Tissue Repair Cell (TRC) technology expands the...
|
